Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Valley City, Utah Clinical Trials

A listing of Valley City, Utah clinical trials actively recruiting patient volunteers.

RESULTS

Found (169) clinical trials

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Phase

4.0 miles

Learn More »

PSD502 in Subjects With Premature Ejaculation

The study will assess whether the bothersome symptoms of premature ejaculation (PE) are helped when treated with PSD502 by answering questionnaires such as the 'Premature Ejaculation Bothersome Evaluation Questionnaire' (PEBEQ) and 'Index of Premature Ejaculation (IPE) and some additional questions about premature ejaculation. The study will also measure the effect ...

Phase

4.82 miles

Learn More »

A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

The reason for this study is to see if the study drug LY3454738 is safe and effective as treatment for participants with hives that are caused by chronic spontaneous urticaria (CSU) and that are not controlled with H1-antihistamines.

Phase

4.82 miles

Learn More »

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease (LRTD), when compared to placebo.

Phase

4.82 miles

Learn More »

Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with fibromyalgia. The study will be 15-18 weeks in duration, including a 1-4 week screening period (dependent upon duration of analgesic medication washout period), followed by a 14-week double-blind, randomized, placebo-controlled treatment period. ...

Phase

4.82 miles

Learn More »

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

The objectives of this study are to evaluate the efficacy, safety and tolerability of ORP-101 in patients with IBS-D. This is a randomized, double-blind, placebo-controlled, 3-arm, 12-week, parallel proof-of-concept study with 2 active arms (50 mg and 100 mg ORP-101, QD) and 1 matching placebo arm, using a responsive adaptive ...

Phase

4.82 miles

Learn More »

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Phase

5.04 miles

Learn More »

Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury

This is a single center, randomized, double-blind study with a subsequent open-label intervention period to explore whether a course of hyperbaric oxygen can ameliorate persistent symptoms after brain injury. In this study, adult men and women with persistent symptoms 6 months to 10 years after injury will be randomized to ...

Phase

5.12 miles

Learn More »

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

This is a randomized, placebo-controlled, phase 2 study is to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a CMV-Seropositive living donor. The intent of the study is to administer three doses of the study drug (HB-101 or placebo) prior to ...

Phase

5.12 miles

Learn More »

A Study of CCX140-B in Subjects With FSGS

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) to be conducted in the North America, Europe and Australia. The aim of this study is to evaluate the effect of treatment with CCX140-B, a selective antagonist of ...

Phase

5.87 miles

Learn More »